APL-9796

Phase 2Small molecule

AApollo Therapeutics Ltd

APL-9796 is one of 46 small molecule programs targeting Pulmonary Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary HypertensionRecruiting

Pulmonary HypertensionPhase 2

Recruiting

Competition

Competitive Landscape

53 competitors in Pulmonary Hypertension

#DrugCompanyPhaseTrials

Viagra

VViatris Specialty LLC

Approved

22 2

Letairis

Gilead

Approved

7 3

Cialis

Eli Lilly

Approved

6 4

Adempas

Bayer

Approved

6 5

Tracleer

Johnson & Johnson

Approved

6 6

Remodulin

United Therapeutics

Approved

5 7

Opsumit

Johnson & Johnson

Approved

5 8

Primacor

Sanofi

Approved

4 9

Levitra

Bayer

Approved

2 10

Uptravi

Johnson & Johnson

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Pulmonary Hypertension

NCT06846554

Clinical

Trials by Indication[1]

Pulmonary Hypertension1 trial

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

Recruiting·AApollo Therapeutics Ltd·Phase 2·NCT06846554·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for APL-9796. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APL-9796 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APL-9796. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Apollo Therapeutics Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AApollo Therapeutics Ltd

APL-9796

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Pulmonary Hypertension1 trial

References

Drug Info

Quick Facts

Related News